Screener
Cytokinetics CYTK Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Property and equipment, net | 78,916 | 79,194 |
| Operating lease right-of-use assets | 72,896 | 75,979 |
| Inventories, long-term | 6,529 | — |
| Other assets | 19,406 | 17,341 |
| Total assets | $1,924,551 | $1,424,537 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $20,510 | $22,337 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's deferred tax assets and other non-current assets?
- Cytokinetics (CYTK) reported deferred tax assets and other non-current assets of $19.41M in Q2 2026.
- How has Cytokinetics's deferred tax assets and other non-current assets changed year-over-year?
- Cytokinetics's deferred tax assets and other non-current assets increased by 33.3% year-over-year, from $14.55M to $19.41M.
- What is the long-term trend for Cytokinetics's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Cytokinetics's deferred tax assets and other non-current assets has grown at a 22.2% compound annual growth rate (CAGR), from $6.36M to $17.34M.
- What does deferred tax assets and other non-current assets mean?
- Combined balance of non-current deferred tax assets and other miscellaneous non-current assets.
Ask your AI about Cytokinetics's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude